These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


303 related items for PubMed ID: 28092986

  • 1. The Treatment of Primary Orthostatic Hypotension.
    Hale GM, Valdes J, Brenner M.
    Ann Pharmacother; 2017 May; 51(5):417-428. PubMed ID: 28092986
    [Abstract] [Full Text] [Related]

  • 2. Atomoxetine for Orthostatic Hypotension in an Elderly Patient Over 10 Weeks: A Case Report.
    Hale GM, Brenner M.
    Pharmacotherapy; 2015 Sep; 35(9):e141-8. PubMed ID: 26406777
    [Abstract] [Full Text] [Related]

  • 3. Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
    Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K.
    Ann Pharmacother; 2018 Dec; 52(12):1182-1194. PubMed ID: 29972032
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
    Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I, Shibao CA.
    Hypertension; 2014 Dec; 64(6):1235-40. PubMed ID: 25185131
    [Abstract] [Full Text] [Related]

  • 5. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
    Kremens D, Lew M, Claassen D, Goodman BP.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):29-31. PubMed ID: 28674867
    [No Abstract] [Full Text] [Related]

  • 6. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Jul; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 7. Chemical pharmacotherapy for the treatment of orthostatic hypotension.
    Cheshire WP.
    Expert Opin Pharmacother; 2019 Feb; 20(2):187-199. PubMed ID: 30376728
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.
    Patrick K, Martin T.
    JBI Database System Rev Implement Rep; 2017 Sep; 15(9):2287-2294. PubMed ID: 28902695
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension.
    Byun JI, Kim DY, Moon J, Shin HR, Sunwoo JS, Lee WJ, Lee HS, Park KI, Lee ST, Jung KH, Jung KY, Kim M, Lee SK, Chu K.
    Ann Clin Transl Neurol; 2020 Jan; 7(1):112-120. PubMed ID: 31856425
    [Abstract] [Full Text] [Related]

  • 10. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP, Claassen D, Mehdirad A.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract] [Full Text] [Related]

  • 11. New developments in the management of neurogenic orthostatic hypotension.
    Biaggioni I.
    Curr Cardiol Rep; 2014 Nov; 16(11):542. PubMed ID: 25303896
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.
    Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, Kim TJ, Lee WJ, Lee HS, Jun JS, Park KI, Lee ST, Jung KH, Jung KY, Lee SK, Chu K.
    Neurology; 2017 Sep 05; 89(10):1078-1086. PubMed ID: 28794253
    [Abstract] [Full Text] [Related]

  • 13. Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients.
    Lessing JK, Kram SJ, Levy JH, Grecu LM, Katz JN.
    J Cardiothorac Vasc Anesth; 2024 Jan 05; 38(1):155-161. PubMed ID: 37838507
    [Abstract] [Full Text] [Related]

  • 14. Treatment of orthostatic hypotension with midodrine and octreotide.
    Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR.
    J Clin Endocrinol Metab; 1998 Feb 05; 83(2):339-43. PubMed ID: 9467537
    [Abstract] [Full Text] [Related]

  • 15. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension.
    McClellan KJ, Wiseman LR, Wilde MI.
    Drugs Aging; 1998 Jan 05; 12(1):76-86. PubMed ID: 9467688
    [Abstract] [Full Text] [Related]

  • 16. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 05; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 17. [Arterial hypotension: behind the scenes].
    Roukain A, Pechere-Bertschi A.
    Rev Med Suisse; 2018 Sep 12; 14(618):1581-1587. PubMed ID: 30226654
    [Abstract] [Full Text] [Related]

  • 18. Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa.
    Kurihara J, Takata Y, Suzuki S, Okubo Y, Kato H.
    Biol Pharm Bull; 2000 Dec 12; 23(12):1445-9. PubMed ID: 11145175
    [Abstract] [Full Text] [Related]

  • 19. Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
    Goodman BP, Gupta F.
    Clin Auton Res; 2017 Jul 12; 27(Suppl 1):21-23. PubMed ID: 28631222
    [No Abstract] [Full Text] [Related]

  • 20. New Horizons in orthostatic hypotension.
    Frith J, Parry SW.
    Age Ageing; 2017 Mar 01; 46(2):168-174. PubMed ID: 27864240
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.